NCT05461352View on ClinicalTrials.gov

Long-Term Study of TS-142 in Patients with Insomnia

PHASE3CompletedINTERVENTIONAL
Enrollment

401

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

March 7, 2024

Study Completion Date

March 7, 2024

Conditions
Patients with Insomnia
Interventions
DRUG

TS-142 5 mg

Participants received repeated doses of 5 mg of TS-142 (oral tablet)

DRUG

TS-142 10 mg

Participants received repeated doses of 10 mg of TS-142 (oral tablet)

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Tokyo

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY